OOIR: Observatory of International Research

Papers

(The TQCC of Expert Review of Pharmacoeconomics & Outcomes Research is 3. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications	48
Distinguishing features in the assessment of mHealth apps	38
Real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic	37
Tools to assess the quality of life in patients with Parkinson’s disease: a systematic review	27
Health-related quality of life in patients with chronic kidney disease	27
First-line atezolizumab plus chemotherapy in advanced non-squamous non-small cell lung cancer: a cost-effectiveness analysis from China	26
Will the Markov model and partitioned survival model lead to different results? A review of recent economic evidence of cancer treatments	23
Evaluation instruments for executive functions in children and adolescents: a systematic review	20
Outcome measures for physical fatigue in individuals with multiple sclerosis: a systematic review	18
Micro-costing diagnostics in oncology: from single-gene testing to whole- genome sequencing	17
A comparison of measurement properties between UK SF-6D and English EQ-5D-5L and Thai EQ-5D-5L value sets in general Thai population	17
Cost-effectiveness of using a 20-valent pneumococcal conjugate vaccine to directly protect adults in England at elevated risk of pneumococcal disease	16
Prevalence of chronic respiratory morbidity, length of stay, inpatient readmissions, and costs among extremely preterm infants with bronchopulmonary dysplasia	16
Cost-effectiveness of adding durvalumab to first-line chemotherapy for extensive-stage small-cell lung cancer in China	15
Resource utilization, work productivity and costs in patients with hidradenitis suppurativa: a cost-of-illness study	15
Comparative efficacy and safety of rimegepant, ubrogepant, and lasmiditan for acute treatment of migraine: a network meta-analysis	14
Gap analysis in manufacturing, innovation and marketing of medical devices in the Asia-Pacific region	13
A review of quality-of-life in elderly osteoarthritis	12
Estimating the economic consequences of substance use and substance use disorders	12
Artificial intelligence in outcomes research: a systematic scoping review	12
Productivity loss/gain in cost-effectiveness analyses for vaccines: a systematic review	12
Cost-utility analysis and budget impact of benralizumab as add-on therapy to standard care for severe eosinophilic asthma in Colombia	11
The cost-effectiveness of once-weekly semaglutide compared with other GLP-1 receptor agonists in type 2 Diabetes: a systematic literature review	11
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore	11
Cost-effectiveness analysis of molecular diagnosis by next-generation sequencing versus sequential single testing in metastatic non-small cell lung cancer patients from a south Spanish hospital perspe	10

The pharmacoeconomic impact of follitropin alpha biosimilars in IVF therapy in Europe: a report of the literature	10
Economic burden associated with stroke in India: insights from national sample survey 2017-18	10
Cost of illness in multiple sclerosis by disease characteristics – A review of reviews	10
Costs of medication use among patients with juvenile idiopathic arthritis in the Dutch healthcare system	9
Adapting health technology assessment for drugs, medical devices, and health programs: Methodological considerations from the Indian experience	9
Cost-effectiveness analysis of donafenib versus lenvatinib for first-line treatment of unresectable or metastatic hepatocellular carcinoma	9
Cannabis use among Canadian adults with cancer (2007–2016): results from a national survey	9
All-cause community acquired pneumonia cost by age and risk in real-world conditions of care in Spain	9
Cost-utility of dapagliflozin plus standard treatment compared to standard treatment for the management of heart failure with reduced ejection fraction in Colombia	9
Design of a health-economic Markov model to assess cost-effectiveness and budget impact of the prevention and treatment of depressive disorder	9
An update on the economic burden of type 2 diabetes mellitus in China	9
Not cost-effective at zero price: valuing and paying for combination therapies in cancer	9
Exploring the consistency of the SF-6Dv2 in a breast cancer population	8
Can we achieve affordable cancer medicine prices? Developing a pathway for change	8
Evidence of long-term real-world reduction in healthcare resource utilization following treatment of opioid use disorder with reSET-O, a novel prescription digital therapeutic	8
Cost-utility analysis of dupilumab add on therapy versus standard therapy in adolescents and adults for severe asthma in Colombia	8
Economic burden of comorbidities among COPD Patients hospitalized for acute exacerbations: an analysis of a commercially insured population	8
Understanding long-listed pharmaceutical products without competition in South Korea: policy implications in managing generic entrants and pharmaceutical expenditures	8
Cost-effectiveness of osimertinib versus standard EGFR-TKI as first-line treatment for locally advanced or metastatic EGFR mutation-positive non-small cell lung cancer in Australia	8
Acceptability and willingness to pay for a hypothetical vaccine against SARS CoV-2 by the Brazilian consumer: a cross-sectional study and the implications	8
The Economic and societal burden of multiple sclerosis on lebanese society: a cost-of-illness and quality of life study protocol	7
Impact on hospitalizations of long-term versus short-term therapy with sodium zirconium cyclosilicate during routine outpatient care of patients with hyperkalemia: the recognize I study	7
Cost-effectiveness analysis of olaparib and niraparib as maintenance therapy for women with recurrent platinum-sensitive ovarian cancer	7
Cost-effectiveness of trifluridine/tipiracil as a third-line treatment of metastatic gastric cancer, including adenocarcinoma of the gastrohesophageal junction, among patients previously treated in Gr	7
In-hospital economic burden of anastomotic leakage after colorectal anastomosis surgery: a real-world cost analysis in Italy	7
Assessment of the properties of the EQ-5D-5L in patients with type 2 diabetes mellitus: a systematic review and meta-analysis	7
Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer	7
Durvalumab consolidation therapy in patients with stage III non-small cell lung cancer after concurrent chemoradiation: a China-based cost-effectiveness analysis	7
Can artificial intelligence separate the wheat from the chaff in systematic reviews of health economic articles?	7
Cost-effectiveness analyses of targeted therapy and immunotherapy for advanced non-small cell lung cancer in the United States: a systematic review	7
Burden of illness the first year after diagnosed bladder dysfunction among people with spinal cord injury or multiple sclerosis – a Danish register study	7
Trends in the pricing and reimbursement of new anticancer drugs in South Korea: an analysis of listed anticancer drugs during the past three years	6
Pharmacoeconomics of obesity in China: a scoping review	6
Cost-effectiveness analysis of tofacitinib compared with adalimumab and etanercept in the treatment of severe active rheumatoid arthritis; Iranian experience	6
Health and economic impact of the correct diagnosis of transthyretin cardiac amyloidosis in Spain	6
Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis	6
Budget impact analysis of subcutaneous trastuzumab compared to intravenous trastuzumab in Saudi HER2-positive breast cancer patients	6
Cost-effectiveness analyses comparing cemented, cementless, hybrid and reverse hybrid fixation in total hip arthroplasty: a systematic overview and critical appraisal of the current evidence	6
The economic value of knowing BRCA status: universal BRCA testing for breast cancer prevention	6
Considering potential solutions for limitations and challenges in the health economic evaluation of gene therapies	6
Systematic reviews of machine learning in healthcare: a literature review	6
The impact of changing the funding model for genetic diagnostics and improved access to personalized medicine in oncology	6
Cost-utility analysis of ceftazidime-avibactam versus colistin-meropenem in the treatment of infections due to Carbapenem-resistant Klebsiella pneumoniae in Colombia	5
Assessing the value contribution of bimekizumab for the treatment of moderate-to-severe psoriasis using a multidisciplinary reflective multi-criteria decision analysis	5
Estimating the annual economic burden for the management of patients with transthyretin amyloid polyneuropathy in Spain	5
Healthcare resource utilization in patients with newly diagnosed atrial fibrillation in the United States	5
A systematic review and meta-regression of studies eliciting willingness-to-pay per quality-adjusted life year in the general population	5
Direct medical costs of breast cancer in Jordan: cost drivers and predictors	5
Economic evaluation of toripalimab plus chemotherapy compared with chemotherapy as first-line treatment for advanced esophageal squamous cell carcinoma in China	5
Assessing the pricing and benefits of oncology products: an update	5

Summary of the 2020 AHRQ research meeting on ‘advancing methods of implementing and evaluating patient experience improvement using consumer assessment of healthcare providers and systems (CAHPS®) sur	5
Tackling reimbursement challenges to fair access to medicines – introduction to the topic	5
A systematic review of cost-effectiveness analyses of continuous versus intermittent renal replacement therapy in acute kidney injury	5
Prevalence and direct costs of potentially inappropriate prescriptions in France: a population-based study	5
Cost-effectiveness of treatments for HER2-positive metastatic breast cancer and associated metastases: an overview of systematic reviews	4
Cost-effectiveness of dapagliflozin compared to DPP-4 inhibitors as combination therapy with metformin in the treatment of type 2 diabetes mellitus without established cardiovascular disease in Colomb	4
A pharmacovigilance study to quantify the strength of association between the combination of antimalarial drugs and azithromycin and cardiac arrhythmias: implications for the treatment of COVID-19.	4
Impact of single-pill combinations versus free-equivalent combinations on adherence and persistence in patients with hypertension and dyslipidemia: a systematic literature review and meta-analysis	4
The costs of treatment resistant depression: evidence from a survey among Italian patients	4
How can societal culture and values influence health and rehabilitation outcomes?	4
Value elements and methods of value-based pricing for drugs in Japan: a systematic review	4
Cost-effectiveness of camrelizumab plus chemotherapy versus chemotherapy alone as first-line therapy in advanced or metastatic esophageal squamous cell carcinoma	4
Economic evaluation of ivabradine in treatment of patients with heart failure: a systematic review	4
A review of caregiver costs included in cost-of-illness studies	4
Early technology assessment of using whole genome sequencing in personalized oncology	4
Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update	4
Incorporating health inequality impact into economic evaluation in low- and middle-income countries: a systematic review	4
Burden of disease and costs of infections associated with cardiac implantable electronic devices	4
Budget impact analysis of medicines: estimated values versus real-world evidence and the implications	4
Identification of risk factors of 30-day readmission and 180-day in-hospital mortality, and its corresponding relative importance in patients with Ischemic heart disease: a machine learning approach	4
Preference of young adults for COVID-19 vaccination in the United Kingdom: a discrete choice experiment	4
The economic burden of biologic disease-modifying antirheumatic drugs in rheumatoid arthritis patients in the United States	4
Budget impact of introducing subcutaneous vedolizumab as a maintenance therapy in biologic-naïve and biologic-experienced patients with ulcerative colitis in France	4
Predicting key drivers for health care expenditure growth in the Middle East region: a Grossman-PLS modeling approach	4
Bringing the patient’s perspectives forward in drug development and health-care evaluation	4
Cost-related nonadherence for prescription medications: a cross-sectional study in Jordan	4
The impact of fibrodysplasia ossificans progressiva (FOP) on patients and their family members: results from an international burden of illness survey	4
Assessment of women’s treatment preferences for vasomotor symptoms due to menopause	4
Assessing the impact of kidney cancer-related premature mortality and productivity loss in Greece and Portugal	4
A comparison of six approaches for measuring utility values among patients with locally advanced cervical cancer	4
Recommendations for economic evaluations of cell and gene therapies: a systematic literature review with critical appraisal	4
Cost-effectiveness analysis of trastuzumab for early breast cancer in Brazil	3
Comparative cost-effectiveness of radiotherapy among older women with hormone receptor positive early-stage breast cancer	3
Determination of the economically justifiable price of cenobamate in the treatment of focal-onset seizures in adult patients with drug-resistant epilepsy in Spain	3
Pharmacoeconomic evaluation of dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus: a systematic literature review	3
Tenecteplase in managing acute ischemic stroke: a long-term cost–utility analysis in Iran	3
Cost-effectiveness of acalabrutinib regimens in treatment-naïve chronic lymphocytic leukemia in the United States	3
The substantial costs to society associated with obesity – a Danish register-based study based on 2002-2018 data	3
How do hospital characteristics and ties relate to the uptake of second-generation biosimilars? A longitudinal analysis of Portuguese NHS hospitals, 2015–2021	3
Cost-benefit analysis of hepatic resection, radiofrequency ablation and liver transplantation in small hepatocellular carcinoma	3
Cost-effectiveness of pharmacist-led care versus usual care in type 2 diabetic Jordanians: a Markov modeling of cardiovascular diseases prevention	3
Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck	3
Patient associations and clinical oncology research: how much does a patient’s voice really matter?	3
Economic evaluation of reproductive carrier screening for recessive genetic conditions: a systematic review	3
The societal costs of multiple sclerosis in Lebanon: a cross-sectional study	3
Patient preferences for elagolix and leuprolide for treating endometriosis-related pain in the United States	3
The impact of statistical properties of incremental monetary net benefit and incremental cost-effectiveness ratio on health economic modeling choices	3
A landscape analysis and discussion of value of gene therapies for sickle cell disease	3
The impact of universal health coverage and COVID-19 pandemic on out-of-pocket expenses in Thailand: an analysis of household survey from 1994 to 2021	3
A pre-vaccine analysis using the Health Belief Model to explain parents’ willingness to vaccinate (WTV) their children in the United States: implications for vaccination programs	3
Moving beyond the stage: how characteristics at diagnosis dictate treatment and treatment-related quality of life year losses for women with early stage invasive breast cancer	3
Cost-effectiveness analysis of the first‐line EGFR‐TKIs in patients with advanced EGFR-mutated non-small-cell lung cancer	3
Design and testing of a health economic Markov model for treatment of anorexia nervosa	3
Capturing the holistic value of biosimilars in Europe – part 1: a historical perspective	3
Value-based health care in Western countries: a scoping review on the implementation of patient-reported-outcomes sets for hospital-based interventions	3
Canadian French translation and linguistic validation of the health-related quality of life utility measure for pre-school children	3
Cost-effectiveness of nivolumab in advanced melanoma: a drug review	3
The affordability of adding a direct-acting oral anticoagulant to the national list of essential medicine for patients with non-valvular atrial fibrillation in Thailand: a budget impact analysis	3
Burden of ischemic heart disease in Spain: incidence, hospital mortality and costs of hospital care	3
Cost-utility analysis of the anti-TNF therapy for rheumatoid arthritis in a real-world based model	3
Multicriteria decision analysis in health care decision in oncology: a systematic review	3
Contemporary outcomes studies to identify and mitigate the risk in patients with premature cardiovascular disease	3
Estimation of the economic burden of atrial fibrillation-related stroke in Greece	3
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma	3
Budget impact and pharmacy costs with targeted use of oliceridine for postsurgical pain in patients at high risk of opioid-related adverse events	3
A systematic review of cost-effectiveness analyses across the acute kidney injury landscape	3